RAM
GSK icon

Roanoke Asset Management’s GSK GSK Stock Holding History

Roanoke Asset Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,703
Closed -$1.3M – 98
2024
Q3 		$1.3M Sell
31,703
-640
-2% -$26.2K 0.41% 55
2024
Q2 		$1.25M Sell
32,343
-440
-1% -$18.5K 0.41% 55
2024
Q1 		$1.41M Sell
32,783
-244
-0.7% -$10.1K 0.46% 53
2023
Q4 		$1.22M Buy
33,027
+94
+0.3% +$3.38K 0.45% 54
2023
Q3 		$1.19M Sell
32,933
-1,711
-5% -$60.7K 0.49% 54
2023
Q2 		$1.24M Sell
34,644
-2,800
-7% -$100K 0.49% 56
2023
Q1 		$1.33M Hold
37,444
– – 0.57% 56
2022
Q4 		$1.32M Sell
37,444
-2,800
-7% -$93.3K 0.6% 54
2022
Q3 		$1.18M Sell
40,244
-180
-0.4% -$6.82K 0.56% 55
2022
Q2 		$2.2M Buy
40,424
+4,264
+12% +$235K 0.99% 37
2022
Q1 		$1.97M Buy
36,160
+800
+2% +$43.5K 0.73% 46
2021
Q4 		$1.95M Buy
35,360
+2,696
+8% +$140K 0.65% 45
2021
Q3 		$1.56M Hold
32,664
– – 0.55% 48
2021
Q2 		$1.63M Buy
32,664
+1,036
+3% +$49.8K 0.56% 47
2021
Q1 		$1.41M Hold
31,628
– – 0.61% 45
2020
Q4 		$1.46M Sell
31,628
-2,880
-8% -$132K 0.69% 44
2020
Q3 		$1.62M Hold
34,508
– – 0.88% 40
2020
Q2 		$1.76M Buy
34,508
+520
+2% +$26.7K 1.02% 34
2020
Q1 		$1.61M Buy
33,988
+336
+1% +$17.9K 1.08% 32
2019
Q4 		$1.98M Buy
33,652
+27,188
+421% +$1.51M 0.99% 38
2019
Q3 		$345K Sell
6,464
-960
-13% -$49.4K 0.16% 78
2019
Q2 		$371K Buy
7,424
+320
+5% +$16.1K 0.17% 78
2019
Q1 		$371K Buy
7,104
+344
+5% +$17.2K 0.17% 79
2018
Q4 		$323K Buy
+6,760
New +$333K 0.17% 80
2015
Q4 		– Sell
-16,120
Closed -$775K – 111
2015
Q3 		$775K Buy
16,120
+120
+0.8% +$6.25K 0.28% 72
2015
Q2 		$833K Buy
16,000
+2,040
+15% +$115K 0.27% 73
2015
Q1 		$805K Buy
13,960
+640
+5% +$36.7K 0.26% 74
2014
Q4 		$712K Buy
+13,320
New +$745K 0.24% 73

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Roanoke Asset Management's GSK Position: Q4 2024 in Review

Roanoke Asset Management sold out of GSK (GSK) in Q4 2024, closing a stake of 31,703 shares — an estimated $1.3M sold.

Roanoke Asset Management first reported a position in GSK in Q4 2014 and held it in 28 quarters. The position peaked at $2.2M in Q2 2022. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

  • Roanoke Asset Management reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
  • Roanoke Asset Management sold 31,703 GSK shares in Q4 2024, an estimated $1.3M.
  • Roanoke Asset Management first reported a position in GSK in Q4 2014 and held it in 28 quarters.
  • Roanoke Asset Management's GSK position peaked at $2.2M in Q2 2022.
  • 848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on Roanoke Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.